Claims for Patent: 7,902,344
✉ Email this page to a colleague
Summary for Patent: 7,902,344
Title: | Antibodies with increased affinities for anthrax antigens |
Abstract: | The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection of infection by Bacillus anthracis. |
Inventor(s): | Harvey; Barrett R. (Austin, TX), Georgiou; George (Austin, TX), Iverson; Brent L. (Austin, TX) |
Assignee: | The Board of Regents of The University of Texas System (Austin, TX) |
Application Number: | 11/179,244 |
Patent Claims: | 1. An isolated nucleic acid encoding an isolated antibody or fragment thereof that binds immunologically to Bacillus anthracis protective antigen and comprises the variable
light and variable heavy chain of SEQ ID NO:21, with the exception that the variable light and variable heavy chain collectively comprise at least three modifications selected from the group consisting of: I21V, S22G, L33S, Q38R, L46F, Q55L, S56P, T74A,
S76N, Q78L, L94P, S7P, K19R, S30N, T57S, K62R, K64E, T68I, and M80L; wherein said I21V, S22G, L33S, Q38R, L46F, Q55L, S56P, T74A, S76N, Q78L and L94P are in the variable light chain and wherein said S7P, K19R, S30N, T57S, K62R, K64E, T68I and M80L are
in the variable heavy chain.
2. The isolated nucleic acid of claim 1, further defined as encoding the variable light chain of SEQ ID NO:23 or SEQ ID NO:25. 3. The isolated nucleic acid of claim 1, further defined as encoding the variable heavy chain of SEQ ID NO:23 or SEQ ID NO:25. 4. The isolated nucleic acid of claim 1, further defined as encoding the polypeptide of SEQ ID NO:23. 5. The isolated nucleic acid of claim 1, further defined as encoding the polypeptide of SEQ ID NO:25. |
Details for Patent 7,902,344
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Emergent Biodefense Operations Lansing Llc | BIOTHRAX | anthrax vaccine adsorbed | Injection | 103821 | 11/12/1998 | ⤷ Try a Trial | 2022-07-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.